AR117458A1 - COMPOSITIONS OF ARNi AGENTS FOR AMYLOID PRECURSOR PROTEIN (APP) AND THEIR METHODS OF USE - Google Patents

COMPOSITIONS OF ARNi AGENTS FOR AMYLOID PRECURSOR PROTEIN (APP) AND THEIR METHODS OF USE

Info

Publication number
AR117458A1
AR117458A1 ARP190103781A ARP190103781A AR117458A1 AR 117458 A1 AR117458 A1 AR 117458A1 AR P190103781 A ARP190103781 A AR P190103781A AR P190103781 A ARP190103781 A AR P190103781A AR 117458 A1 AR117458 A1 AR 117458A1
Authority
AR
Argentina
Prior art keywords
agents
methods
app
compositions
arni
Prior art date
Application number
ARP190103781A
Other languages
Spanish (es)
Inventor
Kevin Fitzgerald
Mangala Meenakshi Soundarapandian
Patrick Haslett
Adam Castoreno
Mark Keating
Vasant Jadhav
Martin Maier
Jayaprakash Nair
Kirk Brown
Stuart Milstein
Original Assignee
Alnylam Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alnylam Pharmaceuticals Inc filed Critical Alnylam Pharmaceuticals Inc
Publication of AR117458A1 publication Critical patent/AR117458A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Agentes y composiciones de ácido ribonucleico de hebra doble (ARNihd) dirigidos al gen APP, métodos para inhibir la expresión de un gen APP y métodos de tratamiento de sujetos que padecen una enfermedad o trastorno asociado a APP, tal como una angiopatía amiloide cerebral (CAA) y el mal de Alzheimer familiar de inicio temprano (EOFAD o eFAD), usando dichos agentes y composiciones de ARNihd.Double-stranded ribonucleic acid (dRNA) agents and compositions targeting the APP gene, methods of inhibiting the expression of an APP gene, and methods of treating subjects suffering from an APP-associated disease or disorder, such as cerebral amyloid angiopathy (CAA). ) and early-onset familial Alzheimer's disease (EOFAD or eFAD), using such agents and dRNA compositions.

ARP190103781A 2018-12-19 2019-12-19 COMPOSITIONS OF ARNi AGENTS FOR AMYLOID PRECURSOR PROTEIN (APP) AND THEIR METHODS OF USE AR117458A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862781774P 2018-12-19 2018-12-19

Publications (1)

Publication Number Publication Date
AR117458A1 true AR117458A1 (en) 2021-08-04

Family

ID=77568198

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190103781A AR117458A1 (en) 2018-12-19 2019-12-19 COMPOSITIONS OF ARNi AGENTS FOR AMYLOID PRECURSOR PROTEIN (APP) AND THEIR METHODS OF USE

Country Status (1)

Country Link
AR (1) AR117458A1 (en)

Similar Documents

Publication Publication Date Title
CL2020002401A1 (en) Arni compositions of 17 b-hydroxysteroid dehydrogenases type 13 (hsd17b13) and methods of use thereof.
CO2021009163A2 (en) Amyloid precursor protein (app) arni agent compositions and method of use thereof
DOP2019000132A (en) COMPOSITIONS OF SERPINA1 RNAi AND ITS METHODS OF USE OF THE SAME.
EA201890308A1 (en) SUBSTITUTED ASO COMPOUNDS AS IRAK-4 INHIBITORS
CL2018000198A1 (en) Compositions of transthyretin (ttr) arni and methods for use for the treatment or prevention of diseases associated with ttr
EA201890307A1 (en) INDASOLIC AND AZAINDASOLIC COMPOUNDS AS IRAK-4 INHIBITORS
CL2020002865A1 (en) Arni compositions against angiotensinogen (agt) and methods for their use
ECSP20046463A (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING DISEASES INVOLVING TISSUES WITH ACIDIC OR HYPOXIC DISEASES
BR112016015236A2 (en) serine / threonine kinase inhibitors
CL2019003324A1 (en) Salts and solid forms of a monobactam antibiotic. (divisional request 201800745)
WO2015106128A3 (en) Rnai agents modified at the 4'-c-position
CO6501189A2 (en) DERIVATIVES OF OXAZINE AND ITS USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS
UY34701A (en) SOLID FORMS OF A THIOPHOSPHORAMIDATE NUCLEOTIDE PROFIT
CO2021002691A2 (en) Compositions and methods for editing the hydroxy acid oxidase 1 (hao1) gene to treat primary hyperoxaluria type 1 (ph1)
CO2022009787A2 (en) Human chromosome 9 open reading frame 72 (c9orf72) rni agents, compositions and methods of use thereof
CL2022001256A1 (en) Methods and compositions for treating a disorder associated with agt angiotensinogen
CO2021001277A2 (en) Triazole glycolate oxidase inhibitors
EP4285993A3 (en) Growth differentiation factor 15 as biomarker for metformin
NI202000085A (en) MODULATORS OF APOL1 EXPRESSION
UY37800A (en) IRNA AGENTS FOR THE INHIBITION OF ALFA-ENaC EXPRESSION AND METHODS OF USE
BR112022009710A2 (en) COMBINATION THERAPY COMPRISING AN ALK2 INHIBITOR AND A JAK2 INHIBITOR
BRPI0416812A (en) Methods and reagents for the treatment of inflammatory disorders
CO2021008187A2 (en) Compositions and methods for treating and preventing amyotrophic lateral sclerosis
AR120341A1 (en) COMPOSITIONS OF RNAi AGENTS AGAINST HUNTINGTINE (HTT) AND THEIR METHODS OF USE
EA201891319A1 (en) COMPOUNDS OF ALKYDYDYDROCHINOLINSULPHONAMIDE